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Abstract
Tumor angiogenesis is regulated by a dynamic cross-
talk between tumor cells and the host microenviron-
ment. Because membrane vesicles shed by tumor cells
are known to mediate several tumor–host interactions,
we determined whether vesicles might also stimulate
angiogenesis. Vesicles shed by human ovarian carci-
nomacell linesCABA I andA2780 stimulated themotility
and invasiveness of endothelial cells in vitro. Enzyme-
linked immunosorbent assay and Western blot analy-
sis revealed relevant amounts of vascular endothelial
growth factor (VEGF) and the twomatrixmetalloprotein-
ases MMP-2 and MMP-9, but not fibroblast growth
factor-2, contained in shed vesicles. An A2780 cell–
derived clone transfected to overexpress VEGF shed the
same amount of vesicles as did a control clone, but
contained significantly more VEGF within the vesicles.
Despite a greater amount of VEGF in vesicles of the over-
expressing clone, vesicles of both clones stimulated en-
dothelial cell motility to comparable levels, suggesting
that VEGF was stored within the vesicle and was un-
available. Only following vesicle burst induced by acidic
pH (a characteristic of the tumormicroenvironment) was
VEGF released, leading to significantly higher stimu-
lation of cell motility. Thus, tumor-shed membrane vesi-
cles carry VEGF and release it in a bioactive form in
conditions typical of the tumor microenvironment.
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Introduction
The development of new blood vessels is essential for the
progression of solid tumors and the development of distant
metastasis [1,2]. Angiogenesis is triggered by a shift in the
normal balance between positive and negative effectors of
angiogenesis, which favors activators [3]. Among angio-
genic stimuli, vascular endothelial growth factor (VEGF) is a
key mediator of physiological and pathological vessel de-
velopment, particularly in tumors [4–6]. VEGF is a soluble
factor that acts through its tyrosine kinase receptors, mainly
VEGFR-2, to directly stimulate endothelial cell functions
relevant to angiogenesis, including proliferation, survival, mi-
gration, and tube formation (reviewed in Refs. [4–6]). VEGF
can also contribute to the formation of tumor neovessels by
mobilizing endothelial progenitor cells from the bone marrow.
Moreover, VEGF regulates vascular permeability, thus playing
a role in the formation of malignant effusions. Aberrant produc-
tion of VEGF has been reported in several tumor types. In-
hibition of the VEGF pathway has shown promise as an
approach to tumor therapy; indeed, VEGF inhibitors are among
the few antiangiogenic compounds that have demonstrated
efficacy in clinical trials [4,6].
Tumor progression is known to involve complex and dy-
namic interactions between cancer cells and the host micro-
environment, with the host actually contributing to tumor
malignancy. In this context, angiogenesis exemplifies the con-
sequences of deregulated cross-talk between tumor cells and
the local microenvironment to favor tumor progression through
the generation of a functional blood vessel system. The inter-
play between tumor and host cells, especially with endothe-
lial cells, is mediated by different mechanisms, including direct
cell–cell contact and secretion of cytokines and bioactive mole-
cules released as either soluble factors or components of shed
membrane vesicles.
Shedding of membrane vesicles from the cell surface is
widely observed in normal and tumor cells in vivo and in vitro
[7]. In normal cells, the process appears to be tightly regulated
because only a limited number of vesicles are shed from de-
fined areas of the plasma membrane in response to specific
stimuli [8]. In contrast, vesicle shedding by tumor cells is largely
a deregulated process because numerous vesicles are consti-
tutively shed from the entire cell surface [9,10].
Shed membrane vesicles carry bioactive molecules that
modulate cell functions in an autocrine and a paracrine manner,
ultimately affecting several aspects of tumor malignancy.
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Tumor-shedvesicles canaffect host immune response [11–14],
promote tumor invasiveness andmetastasis [10,15–19], confer
drug resistance [20], and, as recently described, carry angio-
genic stimuli [21–23].
In the present study, we investigated the role and mo-
lecular mechanisms of tumor-shed membrane vesicles as
mediators of tumor/endothelial cell cross-talk. Our findings
demonstrate that tumor-shed vesicles transport VEGF and
that the bioavailability of angiogenic factor depends on ves-
icle rupture induced by acidic pH in the microenvironment.
Materials and Methods
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were
isolated from umbilical cord veins and grown on 1% gelatin-
coated flasks in M199 supplemented with 10% fetal calf
serum (FCS), 10% newborn calf serum, 20 mM HEPES,
6 U/ml heparin, 2 mM glutamine, 50 mg/ml endothelial cell
growth factor (crude extract from bovine brain), penicillin,
and streptomycin. HUVECs were routinely tested and found
positive for both VEGFR-1 and VEGFR-2. Cells were used
between the third and fifth passages.
The CABA I cell line was established from the ascitic fluid
of an ovarian carcinoma patient not undergoing drug treat-
ment [24]. Cells were grown as monolayers in RPMI 1640
(Euroclone, Devon, UK) with 5% FCS.
Human ovarian carcinoma A2780 cells were cultured in
RPMI 10% FCS. The VEGF-overexpressing variant 1A9-
VS-1 and the control 1A9-VAS-3 were generated from the
A2780-derived cell line 1A9 by stable transfection with
VEGF121 sense (1A9-VS-1) or antisense (1A9-VAS-3) cDNA.
These cells did not express VEGFR-1 nor VEGFR-2, hence
ruling out a possible autocrine activity of VEGF in these cells.
[25]. In this study, the parental 1A9 and control 1A9-VAS-3
cells gave identical results; thus, only results obtained with
1A9-VAS-3 are shown.
Vesicles were isolated from subconfluent viable cell
cultures in which the number of trypan blue–positive dead
cells was negligible. We previously established that shed-
ding of vesicles is optimal when cells are incubated for 6 to
16 hours in serum-containing medium [9]. Thus, ovarian
carcinoma cells were rinsed once with serum-free medium
and cultured for 6 to 16 hours in medium containing 5%
FCS, and supernatants were collected and processed as
described below. The remaining cells were trypsinized and
counted. Vesicles isolated from at least two independent
preparations of conditioned medium were analyzed for each
experimental condition.
Isolation of Membrane Vesicles from
Cell-Conditioned Medium
Vesicles were prepared as described [10]. Conditioned
medium obtained as above was centrifuged at 600g for
15 minutes and at 1500g for 15 minutes to remove cells
and large debris. Supernatants were then centrifuged at
100,000g for 1 hour at 4jC. Unless otherwise indicated,
pelleted vesicles were resuspended in phosphate-buffered
saline (PBS), pH 7.4. In some experiments, pellets were re-
suspended in water or in citrate–PBS at different pH values,
as indicated (pH 5.6–6.0). Vesicles were quantified based
on measurements of vesicle-associated protein levels, using
the method of Bradford (Bio-Rad, Milan, Italy), with bovine
serum albumin (BSA; Sigma, St. Louis, MO) as standard.
Electron Microscopy
Scanning electron microscopy (SEM) was carried out on
subconfluent cells grown on coverslips and fixed with 2%
glutaraldehyde in PBS for 30 minutes. Samples were critical
point–dried, glued onto stubs, coated with gold in a SCD040
Balzer Sputterer, and observed using a Philips 505 SEM at
10 to 30 kV.
Ultrastructural morphology of isolated tumor-shed vesi-
cles was analyzed by transmission electron microscopy
(TEM). The ultracentrifugation pellet containing membrane
vesicles was resuspended in PBS (unless otherwise indi-
cated) and applied to collodion-coated grids. After washing,
vesicles were negatively stained with 1% phosphotungstic
acid, brought to pH 7.0 with NaOH, and examined by TEM
as described [10].
Motility and Invasion Assays
Endothelial cell motility and invasiveness were assayed
using modified Boyden chambers with polycarbonate PVP-
free Nucleopore filters (pore size, 8 mm) [26]. Vesicles, added
at the indicated concentrations to the lower compartment
of the chamber, were used as attractants. Buffer alone or
human recombinant VEGF (10 ng/ml; R&D Systems, Min-
neapolis, MN) were used as negative and positive reference
controls, respectively. For motility (chemotaxis), filters were
coated with 0.1% gelatin. For invasion, filters were coated
with a thick layer of the reconstituted basement membrane
Matrigel (0.5 mg/ml; Becton Dickinson, Bedford, MA), which
cells must degrade to migrate through the filter. HUVECs
were detached, washed in DMEM–0.1% BSA, resuspended
in the same medium at a concentration of 5  105 ml1, and
added to the upper compartment of the chamber. After
4 hours (motility) or 6 hours (invasion), filters were stained
with Diff-Quik (Baxter, Dudingen, Switzerland), and migrated
cells in 10 high-power fields were counted. When experi-
mental conditions required the use of different buffers,
variations in endothelial cell motility in various media were
taken into account by expressing the data as migration index:
(cells that migrated to vesicles  cells that migrated to buffer
alone) / (cells that migrated to VEGF  cells that migrated to
buffer alone).
In some experiments, cells were incubated for 30 minutes
with the VEGF receptor-2 inhibitor SU5416 [27] (provided
by Sugen/Pfizer, San Francisco, CA), which was then left for
the duration of the experiment. Before use, SU5416 was
dissolved in DMSO (stock solution, 40 mM) followed by dilu-
tion with medium. Human recombinant TIMP-2 (R&D Sys-
tems), an inhibitor of matrix metalloproteinases, was added
to the cells immediately before seeding in the Boyden
chamber and left throughout the assays.
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Enzyme-Linked Immunosorbent Assay (ELISA) for VEGF
and Fibroblast Growth Factor-2 (FGF-2)
Human VEGF and FGF-2 were measured by ELISA
(Quantikine Human VEGF Immunoassay; R&D Systems).
ELISA for VEGF recognizes human VEGF121 and VEGF165.
The sensitivity of the assays was 9.0 pg/ml for VEGF and
3 pg/ml for FGF-2. Vesicles were exposed to detergents to
release potentially stored cytokines. Assays were conducted
according to the manufacturer’s directions. The amount of
VEGF was normalized to protein content, and data are ex-
pressed as picograms per microgram.
Western Blot Analysis of VEGF
Vesicles (7 mg) from 1A9-VAS-3 and 1A9-VS-1 cells were
resolved by sodium dodecyl sulfate–15% polyacrylamide
gel electrophoresis (SDS-PAGE) under reducing conditions
and transferred to nitrocellulose membranes (Schleicher &
Schuell, Dassel, Germany). Nonspecific binding sites were
blocked by overnight incubation with 10% nonfat dry milk in
PBS containing 0.5%Tween-20. Blotswere incubatedwith anti-
body against human VEGF (clone A-20, 1:250 dilution; Santa
Cruz Biotechnology, Santa Cruz, CA) for 1 hour, followed by
peroxidase-conjugated secondary antibody, in blocking buffer.
After washing, reactive bands were visualized using a chemi-
luminescence detection kit (ECL; Amersham-Pharmacia, Upp-
sala, Sweden).
Zymography
Zymography was performed using SDS–(8%) polyacryl-
amide gels copolymerizedwith 1mg/ml gelatin typeB (Sigma).
Vesicles (10 mg)werediluted in anSDS-PAGEsample buffer in
nonreducing conditions without heating. After electrophoresis,
gels were washed twice for 30 minutes in 2.5% Triton X-100
at room temperature and incubated overnight in collagenase
buffer (50mMTris–HCI, pH 7.6, 100mMNaCl, 0.02%Brij 35,
and 5 mMCaCl2) at 37jC. Gels were stained with Coomassie
BlueR 250 (Bio-Rad) in 30%methanol and 10%acetic acid for
2 hours and destained in the same solution without dye.
Gelatinase activity was visualized as white bands on a dark
background, indicating proteolysis of the substrate. The su-
pernatant of WM983A melanoma cells was used as a refer-
ence standard for MMP-2 and MMP-9.
Reverse Zymography
Vesicles were applied to a 14% polyacrylamide gel poly-
merized with 1 mg/ml gelatin and a 20% (vol/vol) 6 con-
centrated conditioned medium of HT-1080 cells, used as a
source of gelatinases. After electrophoresis, gels were
washed, incubated in collagenase buffer, and stained as
described above for zymography. TIMP-1 and TIMP-2 ap-
peared as dark bands at 28 and 21 kDa, respectively,
corresponding to the areas where gelatin degradation by
gelatinases added to the gel is prevented by inhibitors. The
supernatant of WM983A cells was used as a reference
standard for TIMPs.
Statistical Analysis
Data were analyzed using the Mann-Whitney U test
(differences were considered statistically significant at P V
.05) or ANOVA, followed by Fisher exact text.
Results
Membrane Vesicles Shed by Ovarian Carcinoma Cells
Stimulate Endothelial Cell Motility and Invasiveness
Scanning electron microscopic analysis of the human
ovarian carcinoma cell lines CABA I and A2780 revealed the
vesicle-shedding phenomenon in both cell lines (Figure 1).
Vesicles were released after culture in a serum-containing
medium (Figure 1) but not in a serum-free medium (not
shown), consistent with previous results [10]. Vesicles ap-
peared to bud from the cell plasma membrane. Their mor-
phology and size (300–1200 nm diameter) were similar to
vesicles shed by other tumor cells [9,16–18,21] and were
clearly distinct from significantly smaller exosomes [28]. To
assess whether tumor-shed vesicles might convey angio-
genic stimuli, vesicles shed by CABA I and A2780 cells were
isolated by centrifugation procedures that allow the recovery
of intact vesicles and were tested for their ability to stimulate
two endothelial cell functions relevant to angiogenesis, mo-
tility, and invasiveness. Vesicles derived from both cell lines
stimulated HUVEC motility in a dose-dependent manner,
with a significant induction observed at z3.3 mg (Figure 2, A
and C). Vesicles (5 mg) were also able to stimulate HUVEC
Figure 1. Scanning electron micrograph of CABA I (A) and A2780 (B) cell vesicle shedding.
98 Bioactivity of Vesicle-Associated VEGF Taraboletti et al.
Neoplasia . Vol. 8, No. 2, 2006
invasiveness (Figure 2, B and D), which requires motility as
well as matrix degradation. In both the motility and invasive-
ness assays, the stimulatory effect of vesicles (z3.3 mg) was
significant (P < .05) and comparable to that of the reference
angiogenic factor VEGF (Figure 2). Vesicles were also able
to stimulate endothelial cell proliferation (not shown).
These findings indicate that tumor-derived vesicles are
able to stimulate endothelial cell functions that are crucial to
the process of angiogenesis.
Molecular Characterization of Shed Vesicles
ELISA analysis to determine whether vesicles shed by
CABA I and A2780 cells contained VEGF revealed measur-
able levels of this major angiogenic factor (Figure 3A). A
comparison of vesicles derived from A2780-derived 1A9-
VS-1 cells and transfected with VEGF121 cDNA and from
control 1A9-VAS-3 cells [25] showed that the two cell vari-
ants shed essentially the same amount of vesicles (18.5
and 17.8 mg per 107 cells for 1A9-VAS-3 and 1A9-VS-1, re-
spectively, in the presence of serum; 0.5 and 0.6 mg per
107 cells, respectively, in the absence of serum). However,
vesicles isolated from the VEGF-overexpressing 1A9-VS-1
cells contained more VEGF than did their control cell–
derived counterparts (P = .02; Figure 3A).Western blot analy-
sis of the isolated vesicles using antibodies against human
VEGF confirmed the presence of VEGF121 in the vesicles
derived from 1A9-VS-1 cells, whereas VEGF was only barely
detectable in control cell–shed vesicles (Figure 3B).
ELISA analysis of FGF-2 in shed vesicles revealed no
detectable levels of this angiogenic factor in either CABA I
or A2780 cells (not shown).
Based on our previous findings that vesicles shed by
normal and transformed cells contain matrix metalloprotein-
ases, which modulate several cell functions including inva-
siveness, we analyzed vesicles isolated from CABA I and
A2780, and the two 1A9 variants for the presence of the two
gelatinases MMP-2 and MMP-9. Zymography revealed both
the proenzyme and active forms of MMP-2 in all cell lines,
whereas CABA I and A2780 contained only the MMP-9 pro-
enzyme (Figure 3C). 1A9-VAS-3–shed and 1A9-VS-1–shed
vesicles showed a similar pattern of gelatinases. Vesicles
also contained TIMP-1 and TIMP-2, endogenous inhibitors
of matrix metalloproteinases, as assessed by reverse zymo-
graphy (Figure 3D).
Functional Activity of Vesicle-Associated VEGF
To evaluate the biologic relevance of vesicle-associated
VEGF, we tested whether VEGF contained in shed vesicles
stimulated endothelial cell motility. Vesicles from both cell
variants stimulated endothelial cell motility at degrees com-
parable to the parental cell line A2780 (two-fold increase;
Figures 2C and 4A). Notably, despite the greater VEGF
Figure 2. Effect of tumor cell – shed vesicles on endothelial cell motility and invasiveness. HUVEC motility (A and C) was tested in the Boyden chamber using
isolated vesicles shed by human ovarian carcinoma cells CABA I (A; triangles) and A2780 (C; triangles) used as attractants. VEGF (10 ng/ml; squares) was used
as a reference stimulus. In the invasion assay (B and D), HUVECs were stimulated by vesicles (5 g) shed by CABA I (B) or A2780 (D), or by VEGF (10 ng/ml)
used as a reference stimulus. Data (mean and SD of triplicates) represent the number of cells that migrated in 10 high-power fields (representative of two to four
experiments). *P V .05.
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content in 1A9-VS-1 vesicles (Figure 4A), the vesicles shed
from the two variants had the same stimulatory activity, sug-
gesting that VEGF present in the vesicles was not active/
available for endothelial cells in these conditions.
To test the hypothesis that breakage of vesicles was
required to allow the release of stored bioactive VEGF,
1A9-VS-1–derived vesicles were exposed to hypotonic con-
ditions (water) and tested for their ability to stimulate endo-
thelial cell motility. Vesicles subjected to osmotic shock were
indeed more active in inducing HUVEC motility (P = .02;
Figure 4B), indicating that vesicle burst releases and makes
stored motility factors available to cells.
pH-Dependent Vesicle Break Causes the Release of
Bioactive VEGF
To identify the stimulus that might induce tumor vesicle
rupture and the subsequent release of stimulatory factors
in vivo, we focused on the known acidic extracellular pH in
solid tumors [29,30]. After ultracentrifugation of 1A9-VAS-3–
and 1A9-VS-1–conditionedmedia, isolated vesicles were re-
suspended in buffers at different pH values (7.4–5.6) and
analyzed for morphology and functional activity (stimulation
of HUVEC migration).
TEM and negative staining revealed rounded intact struc-
tures in vesicles treated with physiological buffer (pH 7.4;
Figure 3. Molecular characterization of vesicles shed by human ovarian carcinoma cell lines and transfected variants. (A) ELISA analysis of VEGF in vesicles.
(B) Western blot analysis of vesicle-associated VEGF. (C) Zymographic analysis of vesicle-associated gelatinases. (D) Reverse zymographic analysis of vesicle-
associated TIMP-1 and TIMP-2. Experiments were conducted as described in Materials and Methods.
Figure 4. Stimulation of endothelial cell motility by shed vesicles. (A) Vesicles shed from 1A9-VAS-3 (circles) and 1A9-VS-1 (triangles) were isolated and tested for
their ability to stimulate HUVEC motility (see Figure 2). (B) Vesicles isolated from 1A9-VS-1 cells were resuspended in either PBS (open triangles) or water (filled
triangles), and, after correction of molarity, tested for motogenic activity. Data (mean and SD of triplicates) represent the number of cells that migrated in 10 high-
power fields.
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Figure 5A), whereas a reduction of pH caused a progressive
break of vesicles. At pH 6, intact vesicles were present but
rare, and linear membrane filaments, derived from broken
vesicles, were evident (Figure 5B, arrows); analysis of vesi-
cle pellets resuspended in pH 5.6 buffer revealed a complete
disruption of rounded vesicular structures and only sporadic
membrane fragments and shapeless masses of membrane
remains (Figure 5C).
Analysis of vesicles exposed to buffers at different pH
values for their ability to induce HUVEC motility showed that
1A9-VS-1–derived vesicles exposed to pH 5.6 and 6 were
significantly more active (P < .05) than vesicles exposed to pH
7.4 in inducing endothelial cell motility (Figure 5D). Increased
activity was also observed in vesicles derived from control
1A9-VAS-3 cells exposed to low pH (not shown), presumably
due to endogenous VEGF. However, the pH-associated in-
crease in activity was always higher in vesicles derived from
the VEGF-overexpressing 1A9-VS-1 cells compared to the
control cells (mean increase of 16.2 ± 9.5–fold vs 3.0 ± 0.6–
fold, respectively, at pH 5.6), reflecting differences in VEGF
content. These findings confirm that the break of vesicles
induced by acidic pH results in the release of bioactive VEGF.
The specificity of the effect was tested using the small
molecule inhibitor of the VEGF tyrosine kinase receptor
SU5416 [27] and the physiological inhibitor of matrix metal-
loproteinases TIMP-2. Stimulation of endothelial cell motility
by vesicles was dramatically reduced in the presence of
SU5416 or, to a lesser extent, in the presence of TIMP-2
(Table 1). In contrast, SU5416 only partially reduced vesicle-
stimulated endothelial cell invasion, whereas TIMP-2
blocked this function (Table 1). These findings indicate the
role of VEGF and matrix metalloproteinases as major medi-
ators of vesicle-induced endothelial cell motility and inva-
siveness, respectively.
Discussion
The present study provides evidence that membrane vesi-
cles shed by human ovarian carcinoma cells act as carriers
of active angiogenic stimuli, specifically VEGF, which is able
Figure 5. Effect of pH on vesicle integrity and activity. Freshly isolated 1A9-VS-1–derived vesicle pellets were resuspended in buffers at the indicated pH and
analyzed by TEM with negative staining for changes in morphology (A–C) and motogenic activity (D). (A) Pelleted vesicles resuspended in PBS (pH 7.4), showing
intact rounded vesicle structures. (B) Pelleted vesicles resuspended in buffer at pH 6.0, showing both intact vesicles (short arrow) and small membrane portions
derived from broken vesicles (arrows). (C) Pelleted vesicles resuspended in buffer at pH 5.6, revealing no intact vesicles and only membrane fragments (arrows),
often aggregated in amorphous masses (inset). (D) Chemotactic activity for HUVECs by vesicles derived from 1A9-VS-1 cells and resuspended in buffers at the
indicated pH (neutralized before the assay). Data (mean and SD of triplicates) are expressed as migration index (see Materials and Methods) (representative of
three experiments). *P V .05. Scale bars, 1 m (A–C).
Table 1. Effect of Inhibitors on Vesicle-Induced Endothelial Cell Motility
and Invasiveness.
Inhibitor Motility Invasiveness
Control 100 100
SU5416 5.9 ± 9.4** 39.3 ± 35.5
TIMP-2 34.6 ± 7.6* 13.1 ± 5.7**
Endothelial cell motility and invasiveness in response to vesicles were as-
sayed in the presence of SU5416 (10 mM) or TIMP-2 (1 mg/ml). Data are the
percentages of control migration, after subtraction of baseline motility.
*P < .05.
**P < .02.
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to promote endothelial cell functions relevant to angio-
genesis. In addition, the data show that VEGF is released
in a bioactive form by vesicle break induced by acidic pH.
Shedding of membrane vesicles by tumor cells is known
to mediate tumor cell interaction with the environment and to
contribute to tumor progression [12,18–20,31,32]. Recently,
vesicles shed by tumor cells, platelets, and endothelial cells
themselves have also been implicated in the process of an-
giogenesis. Vesicles have been described to stimulate pro-
angiogenic activities of endothelial cells, including motility,
invasiveness, capillary-like cord formation, and urokinase
plasminogen activator production, to augment the synthesis
of angiogenic factors in tumor cells and to stimulate angio-
genesis in thechickchorioallantoicmembrane [8,21–23].Con-
sistent with those studies, we found that vesicles shed by
ovarian carcinoma cells contain proangiogenic activity, which
is able to stimulate endothelial cell motility and invasiveness.
Different molecular mediators of the angiogenic activity of
vesicles have been identified, including matrix metalloprotein-
ases [8], FGF-2 [21], and sphingomyelin [22]. We also de-
tected vesicle-associated matrix metalloproteinases but not
vesicle-associated FGF-2, although additional studies are
needed to completely exclude a role for this or other angio-
genic factors in our system.With respect to sphingomyelin, our
finding that heated vesicles lose most of their ability to stimu-
late endothelial cell motility (not shown) suggests that heat-
resistant lipids, such as sphingomyelin [22], are not major
players in our system. Instead, we have demonstrated that the
angiogenic factor VEGF can be released by tumor cells as a
component of membrane vesicles. The presence of VEGF in
tumor-shed membrane vesicles was documented by ELISA
and Western blot analysis, and by the finding that vesicles
released by the VEGF-overexpressing 1A9-VS-1 cells con-
tained more VEGF than did the control 1A9-VAS-3 cells.
Vesicles are known to carry a variety of active factors.
Some of these molecules, such as MMP-2, MMP-9, uPA
[18], HLA class I, integrin-b1 [9], FasL [33,34], and sphingo-
myelin [22], are associated with the vesicle membrane and
therefore are readily available. The presence of these mole-
cules might justify the observed chemotactic activity of intact
vesicles. Other vesicle-associated molecules, mostly soluble
factors such as FGF-2 [21], interleukin-1b [35], and TGF-b
[12], are stored within the vesicle. Our study indicates that
VEGF is also carried within the vesicles. Indeed, transmis-
sion electron immunogold analysis of intact vesicles re-
vealed no positive staining for VEGF on the vesicle surface
(not shown). Moreover, vesicle burst caused by either hypo-
tonic shock or low pH increased the motogenic activity of
VEGF-containing vesicles, further indicating the intravesicu-
lar location of this factor. VEGF is normally stored in cyto-
plasmic granules of tumor cells, and such granules might
move inside membrane vesicles during vesicle formation.
The functional activity of VEGF in vesicles is exerted only
after vesicle burst. Indeed, VEGF in intact vesicles is not
available because high-VEGF vesicles from 1A9-VS-1 cells
had the same chemotactic activity as low-VEGF vesicles
from control 1A9-VAS-3 cells. Only when vesicles were
broken did VEGF become bioavailable and did chemotactic
activity increase, with the highest activity in vesicles from
1A9-VS-1 cells. This behavior is similar to that reported for
microvesicle-associated interleukin-1b [35] and vesicle-
associated secreted FasL, which were isolated from ovarian
cancer cells and were functional only when the integrity of the
vesicle membrane was disrupted [33].
How vesicle disruption occurs in vivo is presently unclear,
although different mechanisms have been proposed. Vesi-
cles are unstable structures and, at physiological tempera-
tures (37jC), degrade in a few hours [21]. Fusion with target
cells has also been hypothesized as a mechanism of release
of vesicle-associated factors [21]. Our present study pro-
vides evidence for a mechanism by which a low-pH environ-
ment induces loss of vesicle integrity (as observed by TEM)
and release of their contents, including active VEGF. In fact,
the tumor microenvironment is characterized by interstitial
acidity, often associated with hypoxia [29,30]. Acidification is
the consequence of tumor cell–elevated glycolysis, initially
driven by hypoxia and then becomes constitutive [30]. Nor-
mal cells cannot survive in an acidic environment, whereas
tumor cells are fully adapted to growth in low-pH conditions.
Low tumor pH has been reported to promote malignant pro-
gression by altering the response to radiation and chemo-
therapy, promoting mutagenesis, and stimulating invasive
and metastatic potentials [30]. An acidic environment has
also been reported to stimulate the production of proangio-
genic cytokines [36]. Because hypoxia is known to increase
the synthesis of VEGF though HIF1-a activation [37], it
seems possible that the high levels of VEGF released in
hypoxic–acidic regions reflect both an increased synthesis
of the angiogenic factor and a release from burst vesicles.
The mechanism of pH-dependent vesicle break is still
unclear. Whereas a direct effect of pH on the structure of
the lipid bilayer appears unlikely, acidity might act on pH-
sensitive enzymatic complexes present on the vesicle surface.
The exact mechanism of vesicle burst awaits further study.
In conclusion, this study shows that tumor-shed mem-
brane vesicles act as carriers of VEGF, which contributes to
the cross-talk between tumor and endothelial cells essential
for tumor angiogenesis. Moreover, the present data are the
first to demonstrate that tumor-promoting activities of mem-
brane vesicles are modulated by the extracellular micro-
environment and are activated in conditions of acidic pH
typical of tumor settings.
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